Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15)
Status:
RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The EPIC-15 trial will evaluate the safety, pharmacokinetics, acceptability, and efficacy of pediatric ivermectin (CHILD-IVITAB) in scabies infected children weighing 5 to less than 15 kg. This trial will support future efforts to expand the indication of ivermectin treatment to infants weighing 5 to less than 15 kg to treat numerous NTDs, allowing this young age group equitable access to the numerous benefits of pediatric ivermectin therapy
Phase:
PHASE2
Details
Lead Sponsor:
University of Oxford
Collaborators:
ClinSearch Fundação de Dermatologia Tropical e Venereologia Alfredo da Matta (FUAM) Fundação de Medicina Tropical Dr. Heitor Vieira Dourado University of Basel